Sinovac Biotech has reported that its Covid-19 vaccine, CoronaVac, obtained approval from the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’s Republic of China for usage in children of the age six months to three years. 

The consensus interim recommendations on Covid-19 vaccine use in children aged six months or above in Hong Kong were released by the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases under the Centre for Health Protection of the Department of Health.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The approval is based on clinical trials and studies of Covid-19 inoculation in children and adolescents in the region.

In individuals of this age group, the vaccination schedule approved for use is the same as those in older children. 

Children aged six months to below three years can receive three doses of vaccines. The initial two doses can be given at a gap of 28 days while the third dose can be administered a minimum of three months following the second vaccine dose. 

Furthermore, no restriction is imposed on vaccine usage in immunosuppressed children.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In February, the vaccine received emergency use authorization (EUA) for minors and adults aged over three years in Hong Kong. 

CoronaVac has so far received approvals in over 60 countries and regions globally. 

Last year, Sinovac commenced the Phase III clinical trials of CoronaVac in children aged six months to 17 years. 

Initial data demonstrated that the vaccine possesses a good safety and immunogenicity profile. 

No severe adverse reactions were observed six months following two vaccination doses in children aged six to 35 months.

In July, the Brazilian Health Regulatory Agency (Anvisa) granted EUA for CoronaVac to children aged three to five years.